Anders Karlsson
Anders Karlsson has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Carl Hay
MedImmune, One MedImmune Way, Gaithersburg, MD, 20287, USA.
1 shared publication - David Lowne
MedImmune, Granta Park, Cambridge, CB21 6GH, UK
1 shared publication - Erin Brand
MedImmune, One MedImmune Way, Gaithersburg, MD, 20287, US
1 shared publication - Gene Kurosawa
Division of Biological Sciences, Graduate School of Science, Nagoya University, Nagoya, Aichi 460-8602, Japan
1 shared publication - John G. Elvin
MedImmune, Granta Park, Cambridge, CB21 6GH, UK
1 shared publication - Kris F. Sachsenmeier
MedImmune, One MedImmune Way, Gaithersburg, MD, 20287, USA.
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Springer Nature in Molecular Cancer
- Vol. 12 (1) , 11
Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type
The continued discovery of therapeutic antibodies, which address unmet medical needs, requires the continued discovery of tractable antibody targets. Multiple protein-level target discovery approaches are available and these can be used in combination to extensively survey relevant cell membranomes. In this study, the MDA-MB-231 cell line was selected for membranome survey as it is a ‘triple negative’ breast cancer cell line, which represents a cancer subtype that is aggressive and has few treatment options.
- 1 January 2013
- Published by Springer Nature in Molecular Cancer
- Vol. 12 (1) , 11
Open AccessCombining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type
The continued discovery of therapeutic antibodies, which address unmet medical needs, requires the continued discovery of tractable antibody targets. Multiple protein-level target discovery approaches are available and these can be used in combination to extensively survey relevant cell membranomes. In this study, the MDA-MB-231 cell line was selected for membranome survey as it is a ‘triple negative’ breast cancer cell line, which represents a cancer subtype that is aggressive and has few treatment options.
- 10 May 2011
- Published by Springer Nature
- Vol. 753, 129-142
Membrane Protein Digestion – Comparison of LPI HexaLane with Traditional Techniques
Membrane protein profiling and characterization is of immense importance for the understanding of vital processes taking place across cellular membranes. Traditional techniques used for soluble proteins, such as 2D gel electrophoresis, are sometimes not entirely applicable to membrane protein targets, due to their low abundance and hydrophobic character. New tools have been developed that will accelerate research on membrane protein targets. Lipid-based protein immobilization (LPI) is the core technology in a new approach that enables immobilization and digestion of native membrane proteins inside a flow cell format. The presented method is described in the context of comparing the method to traditional approaches where the sample amount that is digested and analyzed is the same.
- 10 May 2011
- Published by Springer Nature
- Vol. 753, 129-142
Membrane Protein Digestion – Comparison of LPI HexaLane with Traditional Techniques
Membrane protein profiling and characterization is of immense importance for the understanding of vital processes taking place across cellular membranes. Traditional techniques used for soluble proteins, such as 2D gel electrophoresis, are sometimes not entirely applicable to membrane protein targets, due to their low abundance and hydrophobic character. New tools have been developed that will accelerate research on membrane protein targets. Lipid-based protein immobilization (LPI) is the core technology in a new approach that enables immobilization and digestion of native membrane proteins inside a flow cell format. The presented method is described in the context of comparing the method to traditional approaches where the sample amount that is digested and analyzed is the same.